In the middle of the 20th century, science disciplines collided and set the stage for a technology that changed cell research ...

today announced its acquisition of Genovis-owned QED Biosciences ("QED"), a leading provider of antibodies, kits, and recombinant proteins and antigens catering to the diverse needs of the IVD and ...

MBX Biosciences, Inc. (NASDAQ:MBX) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. MBX is a clinical-stage biopharma firm developing a ...

In trading on Wednesday, shares of Neurocrine Biosciences, Inc. (Symbol: NBIX) entered into oversold territory, hitting an RSI reading of 24.6, after changing hands as low as $119.76 per share.

28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data for its Phase 2 clinical study of NBI-1117568 (NBI-'568) in adults with schizophrenia.

Then, the pipeline used molecular barcoded oligo-conjugated Sample Tag antibodies (single-cell multiplexing kit, BD Biosciences) to demultiplex the samples and filter out the cell multiplets. The ...

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection ACCESSWIRE · Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) is in the process of developing its anti-Tau antibody VY7523 for the treatment of patients with Alzheimer's Disease [AD] in a phase 1a single-ascending ...